101410-18-8

Basic information

• Product Name: (S)-2-THIOCARBAMOYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 2R-THIOCARBAMOYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(S)-2-THIOCARBAMOYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;TERT-BUTYL2(S)-THIOCARBAMOYLPYRROLIDINE-1-CARBOXYLATE;1-Pyrrolidinecarboxylic acid, 2-(aMinothioxoMethyl)-, 1,1-diMethylethyl ester, (2S)-;(S)-tert-butyl 2-thiocarbaMoylpyrrolidine-1-carboxylate;(S)-2-Thiocarbamoylpyrrolidine-1-carboxylic acid tert-butyl este;tert-butyl (S)-2-carbamothioylpyrrolidine-1-carboxylate
• CAS NO: 101410-18-8
• Molecular Formula: C₁₀H₁₈N₂O₂S
• Molecular Weight: 230.33
• Mol File: 101410-18-8.mol
• Article Data: 22

Chemical Properties

• Melting Point: 195-199 °C(Solv: tetrahydrofuran (109-99-9))
• Boiling Point: 339.5±52.0 °C(Predicted)
• Appearance: /
• Density: 1.191±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.98±0.20(Predicted)
• CAS DataBase Reference: (S)-2-THIOCARBAMOYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-THIOCARBAMOYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(101410-18-8)
• EPA Substance Registry System: (S)-2-THIOCARBAMOYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(101410-18-8)

Safety Data

• Hazardous Substances Data: 101410-18-8(Hazardous Substances Data)

Usage

General Description

(S)-2-Thiocarbamoyl-pyrrolidine-1-carboxylic acid tert-butyl ester is a chemical compound that is commonly used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. It is a derivative of pyrrolidine, containing a thiocarbamoyl group, and a tert-butyl ester. (S)-2-THIOCARBAMOYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is often used in the production of medications and other bioactive molecules due to its ability to selectively interact with specific biological targets. Its chemical structure and properties make it a valuable building block for the development of new drugs and pharmaceuticals.

Upstream product

• 35150-07-3 (S)-tert-butyl 2-carbamoylpyrrolidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 7531-52-4 L-prolinamide 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 18598-63-5 L-cysteine methyl ester hydrochloride 
• 228244-04-0 tert-butyl (2S)-2-cyanopyrrolidine-1-carboxylate 
• 70138-72-6 (R)-2-carbamoylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 28310-65-8 N-tert-butyloxycarbonyl-proline p-nitrophenyl ester 
• 84890-94-8 (S)-2-Isobutoxycarbonyloxycarbonyl-pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 944030-48-2 tert-butyl (S)-2-(4-phenylthiazol-2-yl)pyrrolidine-1-carboxylate 
• 479067-56-6 (S)-4-phenyl-2-(pyrrolidin-2-yl)thiazole 
• 1310694-94-0 (S)-tert-butyl 2-(4-(4'-(2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)thiazol-2-yl)pyrrolidine-1-carboxylate 
• 1310694-79-1 (S)-2-(5-(4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl)thiazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1310694-78-0 (S)-tert-butyl 2-(4-(4-bromophenyl)thiazol-2-yl)pyrrolidine-1-carboxylate 
• 1005342-78-8 C₁₉H₂₁FN₂O₃S 

Relevant articles and documents

Total synthesis of trans, trans- Sanguinamide B and conformational isomers

The first total synthesis of Sanguinamide B is reported, prepared via an efficient synthetic strategy. The natural product, trans,trans-Sanguinamide B (1), was generated in a thermodynamic ratio with trans,cis-Sanguinamide B (2) and cis,cis-Sanguinamide B

A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide

Starting from the initial lead 4-phenylthiazole 18, a modest HCV inhibitor (EC50 = 9440 nM), a series of structurally related thiazole derivatives has been identified as a novel chemical class of potent and selective HCV NS5A inhibitors. The introduction of a carboxamide group between the thiazole and pyrrolidine ring (42) of compound 18 resulted in a dramatic increase in activity (EC50 = 0.92 nM). However, 42 showed only moderate pharmacokinetic properties and limited oral bioavalability of 18.7% in rats. Further optimization of the substituents at the 4-position of the thiazole ring and pyrrolidine nitrogen of the lead compound 42 led to the identification of compound 57, a highly potent and selective NS5A inhibitor of HCV (EC50 = 4.6 nM), with greater therapeutic index (CC50/EC50 > 10000). Pharmacokinetic studies revealed that compound 57 had a superior oral exposure and desired bioavailability of 45% after oral administration in rats.

HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND

The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention also relates a method for preparing the compounds, and a method for degradation of HMG-CoA reducatase using the compounds, as well as use for prevention or treatment of HMG-CoA reductase related diseases using the compounds.

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.